Steve Brozak's questions to Omeros Corp (OMER) leadership • Q2 2025
Question
Steve Brozak of WBB Securities LLC asked for a comparison between the financial modeling for the upcoming narsoplimab launch and the past launch of OMIDRIA. He also inquired about the level of urgency and enthusiasm among clinicians for narsoplimab, given the severe condition of TA-TMA patients.
Answer
Gregory Demopulos, Founder, Chairman, CEO & President, explained that the narsoplimab launch is more focused than OMIDRIA's due to a smaller number of transplant centers, but declined to provide specific financial projections at this time. Nadia Dac, CCO, added that physicians are eagerly awaiting an approved therapy for this lethal complication and that feedback from the Expanded Access Program has been very positive, highlighting a significant unmet need.